Pear Pongsachareonnont,1,2 Michael Ying Kit Mak,2 Cameron Paul Hurst,3 Wai-Ching Lam2,4 1Vitreo-Retinal Research Unit, Department of Ophthamology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross ...
Pongsachareonnont P+3 more
doaj
Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study [PDF]
Katharina E. Schmid‐Kubista+5 more
openalex +1 more source
Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
Peter K. Kaiser
openalex +2 more sources
Effects of photodynamic therapy on subfoveal blood flow in neovascular age-related macular degeneration patients [PDF]
V. Vinh Moreau-Gaudry+5 more
openalex +1 more source
Potential of autophagy in subretinal fibrosis in neovascular age-related macular degeneration. [PDF]
Blasiak J+5 more
europepmc +1 more source
OCT predictors of retinal atrophy in neovascular age-related macular degeneration treated with aflibercept. [PDF]
Gagliardi OM+8 more
europepmc +1 more source
Five-year Outcome of Aflibercept Administration with "Treat and Extend" for Neovascular Age-Related Macular Degeneration. [PDF]
Wada I+11 more
europepmc +1 more source
Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision [PDF]
O. Shona+3 more
openalex +1 more source
Three-year visual outcomes after brolucizumab in patients with neovascular age-related macular degeneration. [PDF]
Kobayashi Y+4 more
europepmc +1 more source